138 related articles for article (PubMed ID: 33973917)
21. Efficacy of topical povidone-iodine during the first week after ophthalmic surgery.
Isenberg SJ; Apt L; Yoshimori R; Pham C; Lam NK
Am J Ophthalmol; 1997 Jul; 124(1):31-5. PubMed ID: 9222229
[TBL] [Abstract][Full Text] [Related]
22. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.
Halachmi-Eyal O; Lang Y; Keness Y; Miron D
J Cataract Refract Surg; 2009 Dec; 35(12):2109-14. PubMed ID: 19969216
[TBL] [Abstract][Full Text] [Related]
23. A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis.
Ward JB; Siojo LG; Waller SG
Cornea; 1993 May; 12(3):216-21. PubMed ID: 8500334
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of povidone-iodine-containing therapies for treatment of adenoviral conjunctivitis: A systematic review and network meta-analysis.
Chen YS; Hsu CH; Chang HC
Acta Ophthalmol; 2023 Nov; 101(7):826-827. PubMed ID: 37130094
[No Abstract] [Full Text] [Related]
25. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2019 Sep; 205():197. PubMed ID: 31327463
[No Abstract] [Full Text] [Related]
26. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis.
Ramakrishnan S; Vempati J; Baskaran P
Am J Ophthalmol; 2019 Aug; 204():140. PubMed ID: 31235065
[No Abstract] [Full Text] [Related]
27. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Cinal A
Am J Ophthalmol; 2019 Jan; 197():184. PubMed ID: 30389099
[No Abstract] [Full Text] [Related]
28. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis.
Shiuey Y; Ambati BK; Adamis AP
Ophthalmology; 2000 Aug; 107(8):1512-7. PubMed ID: 10919900
[TBL] [Abstract][Full Text] [Related]
29. Skin antisepsis for reducing central venous catheter-related infections.
Lai NM; Lai NA; O'Riordan E; Chaiyakunapruk N; Taylor JE; Tan K
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010140. PubMed ID: 27410189
[TBL] [Abstract][Full Text] [Related]
30. Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial.
Seguin P; Laviolle B; Dahyot-Fizelier C; Dumont R; Veber B; Gergaud S; Asehnoune K; Mimoz O; Donnio PY; Bellissant E; Malledant Y; ;
Crit Care Med; 2014 Jan; 42(1):1-8. PubMed ID: 24105456
[TBL] [Abstract][Full Text] [Related]
31. Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico.
Ramirez-Ortiz MA; Rodriguez-Almaraz M; Ochoa-Diazlopez H; Diaz-Prieto P; Rodriguez-Suárez RS
Br J Ophthalmol; 2007 Nov; 91(11):1430-4. PubMed ID: 17947266
[TBL] [Abstract][Full Text] [Related]
32. Instillation of 5% Povidone-Iodine Ophthalmic Drops Decreases the Respiratory Rate in Children Undergoing Strabismus Surgery: A Randomized Controlled Trial.
Rovner MS; Wolf BJ; Rubin M; Ritter A; Heine CL; Wester TE; Furse CM
J Pediatr Ophthalmol Strabismus; 2019 Nov; 56(6):378-382. PubMed ID: 31743406
[TBL] [Abstract][Full Text] [Related]
33. Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum.
David M; Rumelt S; Weintraub Z
Ophthalmology; 2011 Jul; 118(7):1454-8. PubMed ID: 21439642
[TBL] [Abstract][Full Text] [Related]
34. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study.
Trinavarat A; Atchaneeyasakul LO
J Ocul Pharmacol Ther; 2012 Feb; 28(1):53-8. PubMed ID: 21916618
[TBL] [Abstract][Full Text] [Related]
35. [Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis].
Yabiku ST; Yabiku MM; Bottós KM; Araújo AL; Freitas Dd; Belfort R
Arq Bras Oftalmol; 2011; 74(6):417-21. PubMed ID: 22331114
[TBL] [Abstract][Full Text] [Related]
36. [Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study].
Monnerat N; Bossart W; Thiel MA
Klin Monbl Augenheilkd; 2006 May; 223(5):349-52. PubMed ID: 16705502
[TBL] [Abstract][Full Text] [Related]
37. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.
Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
Arch Ophthalmol; 2001 Oct; 119(10):1487-91. PubMed ID: 11594949
[TBL] [Abstract][Full Text] [Related]
38. Skin preparation for preventing infection following caesarean section.
Hadiati DR; Hakimi M; Nurdiati DS; Masuzawa Y; da Silva Lopes K; Ota E
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007462. PubMed ID: 32580252
[TBL] [Abstract][Full Text] [Related]
39. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
[TBL] [Abstract][Full Text] [Related]
40. Povidone iodine for the treatment of adenoviral conjunctivitis.
Dang RM; Watt K; Hui A
Clin Exp Optom; 2021 Apr; 104(3):308-314. PubMed ID: 33689609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
